beth israel deaconess medical center a harvard medical school teaching hospital

To find a doctor, call 800-667-5356 or click below:

Find a Doctor

Request an Appointment

left banner
right banner
Smaller Larger

Doctor Decisions and Quality of Life

Posted 2/4/2013

Posted in

  A more interesting title for this entry would be: "Does your doctor care about your quality of life?" The absolute answer for all the medical oncologists whom I know is a resounding "yes", but this study suggests that may not always be true. We know that decisions around treatment are very tough, and that patients never have all the information that the doctors do. For early cancer in general, and breast cancer in particular, this issue is usually not a hot one. The choices are between a few standard treatments that carry similar side effects. If there are particular reasons that a woman would be better served by one or another, or if she has other medical problems that would complicate some medications, that is clear. It becomes trickier in cases of advanced disease when the question is always about quality vs quantity of life.

  Patients tend to over-estimate the possible benefit of treatments in advanced cancer. Doctors may quote response statistics, but defining "response" may or may not happen. Are we talking about a number of statistical significance (that may be quite small) or are we talking about a period of time that clearly has value? Immediately we are in a mire of values and subjective choices. While one person might tolerate any side effects in order to prolong life another few weeks or months, someone else might choose otherwise. It seems to me that the defining question must be being certain that the patient fully understands the possibilities (e.g. are we talking about living another week or another six months if treatment X is helpful?) and that respecting the patient's decision. This becomes a long and difficult conversation between doctor and patient, but it is one that must happen. We need to be sure that it is our values, not our doctors', that are driving the choices.

  Here is the abstract and a link to this really interesting study:

How Long and How Well: Oncologists’ AttitudesToward the Relative Value of Life-Prolonging v.

Quality of Life-Enhancing Treatments

Michael A. Kozminski, BA, Peter J. Neumann, PhD, Eric S. Nadler, Aleksandra Jankovic, MSc, Peter A. Ubel, MD

Objective. To determine how oncologists value qualityenhancing v. life-prolonging outcomes attributable to chemotherapy.

Methods. The authors surveyed a random

. The authors surveyed a random

sample of 1379 US medical oncologists (members of the

American Society of Clinical Oncology), presenting them

with 2 scenarios involving a hypothetical new chemotherapy

drug. Given their responses, the authors derived the

implicit cost-effectiveness ratios each physician attributed

to quality-enhancing and life-prolonging chemotherapies.

Results. The authors received responses from 58% of the

. The authors received responses from 58% of the

oncologists surveyed. On average, the responses implied

that oncologists were willing to prescribe treatments that

cost $245,972 per quality-adjusted life-year (QALY; SD

$243,663 per QALY) in life-prolonging situations v. only

$119,082 per QALY (SD $197,048 per QALY) for treatments

that improve quality of life but do not prolong survival (P <

0.001). This difference did not depend on age, gender, percentage

of time in clinical work, or self-reported preparedness

to use and interpret cost-effectiveness information (P

> 0.05 for all specifications). Differences across these situations

persisted even among those who considered themselves

to be “well-prepared” to make cost-effectiveness

decisions.

 Conclusion. Cost-effectiveness thresholds for

oncologists vary widely for life-prolonging chemotherapy

compared to treatments that only enhance quality of life.

This difference suggests that oncologists value length of

survival more highly than quality of life when making chemotherapy

decisions.. (Med Decis Making 2011;31:380–385)

http://www.ncbi.nlm.nih.gov/pubmed/21088130

. To determine how oncologists value qualityenhancing v. life-prolonging outcomes attributable to chemotherapy.. The authors surveyed a random. The authors received responses from 58% of the

Share:

Add your comment

 
 
 

Categories

Archive